Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
AssigneeWisconsin Alumni Research Foundation
InventorsDavid Frazier Jarrard, Bing Yang
Life of this patent
Estimating the term…
Abstract
A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
Claims18
A method for detecting methylation of SEQ ID NO:1 in target DNA isolated from histologically normal prostate cells from a subject, the method comprising the steps of:
- (a) providing a reaction mixture comprising:
- the target DNA isolated from histologically normal prostate cells from the subject or a bisulfite modified form thereof;
- and
- at least one primer complementary to SEQ ID NO:1 or a bisulfite modified form thereof;
- and
- (b) reacting the reaction mixture for a time and at a temperature sufficient to hybridize the at least one primer to SEQ ID NO:1 or the bisulfite modified form thereof and detect methylation of SEQ ID NO:1 in the target DNA.
Dependencies are inferred from the claim text.